CEACAM1 has 11 different splice variants, as reported in some studies in vivo, and restoration of its expression abolishes oncogenicity of tumor cell lines, but when it is expressed de novo it increases the risk of metastasis [48] CEACAM1 has also been proposed as a potential biomarker for breast cancer [49]. This evidence concerns the gene CEACAM1 and neoplasm.